Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19720923 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Study of Combination Immunotherapy for the Generation of HER-2/Neu Specific Cytotoxic T Cells
Condition: Breast Cancer
Intervention: Biological: HER2 CTL vaccine (plus trastuzumab)

Indicates status has not been verified in more than two years